7 completed. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
Follow Malignancies: new trials by email Literature Review of Malignancies trials Research Report on Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies chemotherapy, venetoclax - Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Completed | AbbVie | 143 | 2017-11-08 | 2023-05-22 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers REGN3767, cemiplimab - Malignancies | Phase 1 | Completed | Regeneron Pharmaceuticals | 333 | 2016-11-07 | 2026-11-19 |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 PWT-143 - Malignancies | Phase 1 | Completed | MEI Pharma, Inc. | 35 | 2015-06-29 | 2017-08-29 |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Carfilzomib, Dexamethasone - Neoplasms, Malignancies | Phase 1 | Completed | Emory University | 22 | 2014-08-01 | 2017-02-07 |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies PWT33597 mesylate - Malignancies | Phase 1 | Completed | Pathway Therapeutics, Inc. | 22 | 2011-06-01 | 2012-10-25 |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Aroplatin - Malignancies, B-Cell Lymphoma | Phase 1 | Completed | Agenus Inc. | 21 | 2006-03-01 | 2008-10-27 |
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) CS-1008 (humanized anti-DR5 antibody) - Malignancies, Lymphoma | Phase 1 | Completed | Daiichi Sankyo | 40 | 2007-09-11 |
Neoplasms (7) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neuroblastoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1)
Calcium Dobesilate (1) · Dexamethasone (1) · Drug Therapy (1) · bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II) (1) · carfilzomib (1) · cemiplimab (1) · tigatuzumab (1) · venetoclax (1)
AbbVie (1) · Agenus Inc. (1) · Daiichi Sankyo (1) · Emory University (1) · MEI Pharma, Inc. (1) · Pathway Therapeutics, Inc. (1) · Regeneron Pharmaceuticals (1)
United States (6) · United Kingdom (3) · Australia (2) · Canada (1) · France (1) · Germany (1) · Ireland (1) · Netherlands (1) · South Korea (1) · Switzerland (1)
Bradley C. Carthon, MD, PhD (1) · Pui Leung, MBChB (1)
PMID 29595064, PMID 30458930, PMID 34088831, PMID 38900987, PMID 39368878, PMID 39422598, PMID 40062648, PMID 40266036
2017 (1)